Año 2023 / Volumen 115 / Número 3
Editorial
How strong is the evidence to support statins repurposing for the treatment of cirrhosis?

107-109

DOI: 10.17235/reed.2022.9281/2022

Carlos Moctezuma-Velázquez, Juan G. Abraldes,

Resumen
In this editorial, we briefly mention the studies that support the use of statins to change the natural history of liver cirrhosis, alongside potential biases and flaws that need to be considered when analyzing data. The key message that we want to communicate is that even if current evidence is somehow compelling, it is limited, mostly from observational studies, and in general not enough to formally recommend the prescription of statins in patients with cirrhosis as disease-modifying agents. Finally, we also mention some important facts about the safety of statins in the context of patients with underlying liver disease.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1 Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut. 2020;69(5):953-62.
2 Gu Y, Yang X, Liang H. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231.
3 Alvarado-Tapias E, Montanes R, Brujats A, et al. Carvedilol plus Simvastatin modulates systemic inflammation in cirrhosis with portal hypertension and non-response to B-blockers: randomised double-blind study. Journal of Hepatology. 2022;77:S91.
4 de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-74.
5 Abraldes JG, Villanueva C, Aracil C, et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology. 2016;150(5):1160-70.e3.
6 Young NS, Ioannidis JP, Al-Ubaydli O. Why current publication practices may distort science. PLoS Med. 2008;5(10):e201.
7 Meireles CZ, Pasarin M, Lozano JJ, et al. Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. Shock. 2017;47(3):370-7.
8 Caraceni P, Abraldes JG, Ginès P, et al. The search for disease-modifying agents in d ecompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol. 2021;75 Suppl 1:S118-S34.
9 Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013(1):CD004816.
10 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-98.
11 Verma S, McGuire DK, Bain SC, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487-92.
12 Dickerman BA, García-Albéniz X, Logan RW, et al. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601-6.
13 Yeh YC, Chen YY, Chen PC. Statins were not associated with hepatocellular carcinoma after controlling for time-varying confounders in patients with diabetes. J Clin Epidemiol. 2022;150:98-105.
14 Mahmud N, Chapin S, Goldberg DS, et al. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol. 2022.
15 Cnossen MC, van Essen TA, Ceyisakar IE, et al. Adjusting for confounding by indication in observational studies: a case study in traumatic brain injury. Clin Epidemiol. 2018;10:841-52.
16 Yun B, Ahn SH, Yoon JH, et al. Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study. Hepatol Commun. 2022;6(9):2455-64.
17 Merkel M, Schneider C, Greinert R, et al. Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. Hepatol Commun. 2021;5(10):1755-66.
18 Chiu WC, Shan JC, Yang YH, et al. Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder. Drug Alcohol Depend. 2021;228:109096.
19 Motzkus-Feagans C, Pakyz AL, Ratliff SM, et al. Statin use and infections in Veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38(6):611-8.
20 Hung TH, Tsai CC, Lee HF. Statin use in cirrhotic patients with infectious diseases: A population-based study. PLoS One. 2019;14(4):e0215839.
21 Zou B, Odden MC, Nguyen MH. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022.
22 Kawaguchi Y, Sakamoto Y, Ito D, et al. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. Biosci Trends. 2017;11(5):574-80.
23 Ertefaie A, Small DS, Flory JH, et al. A tutorial on the use of instrumental variables in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(4):357-67.
24 Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020;5(1):31-41.
25 Sung S, Al-Karaghouli M, Kalainy S, et al. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol. 2021;21(1):120.
Artículos relacionados

Editorial

Tratamiento de la trombosis venosa portal en el paciente con cirrosis

DOI: 10.17235/reed.2023.9800/2023

Imagen en Patología Digestiva

Hematoma espontáneo de la pared duodenal

DOI: 10.17235/reed.2023.9793/2023

Carta

Tolvaptan in portal hypertension: real life experience

DOI: 10.17235/reed.2022.9145/2022

Carta

Hemoperitoneo por rotura de varices intraabdominales

DOI: 10.17235/reed.2022.8937/2022

Imagen en Patología Digestiva

Fístula arterioportal traumática de alto flujo. Corrección mediante stent recubierto

DOI: 10.17235/reed.2022.8724/2022

Carta

Patrón cirrótico en la sarcoidosis hepática avanzada

DOI: 10.17235/reed.2021.8446/2021

Imagen en Patología Digestiva

Trombosis portal en un paciente con infección por SARS-CoV-2

DOI: 10.17235/reed.2021.8099/2021

Imagen en Patología Digestiva

Neumatosis portal en paciente con colitis por Salmonella severa

DOI: 10.17235/reed.2021.8090/2021

Imagen en Patología Digestiva

Spontaneous splenoazygos shunt in a patient with portal hypertension: an exceedingly rare occurrence

DOI: 10.17235/reed.2019.6091/2018

Carta

Intestinal infection leads to hepatic portal venous gas.

DOI: 10.17235/reed.2019.6049/2018

Imagen en Patología Digestiva

Rectorragia como forma de presentación de un caso de síndrome de Abernethy en el adulto

DOI: 10.17235/reed.2018.5615/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Imagen en Patología Digestiva

Shunt intrahepático portocava en paciente con quiste hidatídico que comprime vena cava inferior

DOI: 10.17235/reed.2017.4983/2017

Carta al Editor

POEMS syndrome and idiopathic portal hypertension: a possible association

DOI: 10.17235/reed.2017.4623/2016

Instrucciones para citar
Moctezuma-Velázquez C, Abraldes J. How strong is the evidence to support statins repurposing for the treatment of cirrhosis?. 9281/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 1413 veces.
Este artículo ha sido descargado 250 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 14/10/2022

Aceptado: 22/10/2022

Prepublicado: 10/11/2022

Publicado: 07/03/2023

Tiempo de revisión del artículo: 3 días

Tiempo de prepublicación: 27 días

Tiempo de edición del artículo: 144 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas